Processa Pharmaceuticals, Inc. (PCSA) News

Processa Pharmaceuticals, Inc. (PCSA): $3.13

-0.13 (-3.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PCSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

Filter PCSA News Items

PCSA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PCSA News From Around the Web

Below are the latest news stories about Processa Pharmaceuticals Inc that investors may wish to consider to help them evaluate PCSA as an investment opportunity.

Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022

HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and

Yahoo | January 26, 2022

Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | January 17, 2022

Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update

Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announces financial results for the quarter ended September 30, 2021, and provides a corporate update. Dr. David

Yahoo | November 11, 2021

Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis

Next Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine.24-48 hours after PCS6422 administration, 5-FU potency based on systemic exposure per mg of capecitabine was at least 50 x greater than reported for FDA approved capecitabine.The improved metabolism profile and increased potency did not exist 7 days after PCS6422 administration.The timeline of DPD inhibition and

Yahoo | November 4, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST

HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that the Company will report financial results for the quarter ended September 30, 2021 on Thursday November 11, 2021. The Company will host a conference call at 5:30 p.m. Eastern Time on Thursday November

Yahoo | October 26, 2021

What Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares?

If you want to know who really controls Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ), then you'll have to look at the...

Yahoo | October 19, 2021

Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis

HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that they have been cleared by the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis, an unmet medical need cond

Yahoo | October 12, 2021

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in upcoming investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date and Time: 9/22/2021 9:05 AM (ET)Webcast: https://wsw.com/webcast/oppenheim

Yahoo | September 16, 2021

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in upcoming investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date and Time: 9/22/2021 9:05 AM (ET)Webcast: https://wsw.com/webcast/oppenheim

Yahoo | September 16, 2021

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27

HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at the World Orphan Drug Congress USA 2022 Conference, to be held from August 25-27, 2022. Dr. David Young, CEO and Chairman of Processa will deliver a presentation titled “Balancing the Benefit-Risk of an Orph

Yahoo | August 23, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5259 seconds.